// App-Quantinova.ai

OC1.2 : A Phase III randomized, controlled trial of a modified-release hydrocortisone formulation in the treatment of classic congenital adrenal hyperplasia

Researchers

Presenter

  • Deborah Merke

Principal Investigators

  • Ashwini Mallappa

  • Wiebke Arlt

  • Aude Brac de la Perriere

  • Angelica Hirschberg Linden

  • Anders Juul

  • John Newell-Price

  • Colin Perry

  • Alessandro Prete

  • Aled Rees

  • Nicole Reisch

  • Nike Stikkelbroeck

  • Phillippe Touraine

  • Kerry Matlby

  • Peter Treasure

  • John Porter

  • Richard Ross

Medical Centers

  • NIH, United States

  • University of Birmingham, Surrey, United Kingdom

  • Hopital Femme Mere Enfant, France

  • Karolinska Institutet, Sweden

  • Rigshospitalet, Denmark

  • University of Sheffield Medical School, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • University of Cambridge, Cambridge, United Kingdom

  • University of Munich Hospital, Germany

  • Radboud University, Netherlands

  • Sorbonne Universites, Paris, France

  • Diurnal, United Kingdom

  • Peter Treasure Statistical Services, United Kingdom

Locations

  • United States

  • United Kingdom

  • France

  • Sweden

  • Denmark

  • Germany

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Congenital disorder

Disease

  • Congenital adrenal hyperplasia

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxyprogesterone caproate

  • Hydrocortisone

  • Glucocorticoid

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Prednisolone

  • Prednisone

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved